Faith Leaders Arrested on Capitol Hill During Protest Against Trump Immigration Policies and ICE Funding 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
ICE Blocked From Entering Ecuador Consulate in Minneapolis During Immigration Operation 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
U.S. Justice Department Removes DHS Lawyer After Blunt Remarks in Minnesota Immigration Court 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Keir Starmer Faces Political Crisis After Condemning Peter Mandelson Over Epstein Ties 
Trump Appoints Colin McDonald as Assistant Attorney General for National Fraud Enforcement 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
